DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

Completed

Conditions: Prevention of Thromboembolic Events
Atrial Fibrillation

Interventions: Drug: Apixaban

First Posted Date: 2022-07-25

Last Posted Date: 2023-12-12

Lead Sponsor: Bayer

Target Recruit Count: 600

Registration Number: NCT05471830

Locations: 🇺🇸
Bayer, Whippany, New Jersey, United States

An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)

Completed

Conditions: Venous Thromboembolism
Cancer
Treatment of Venous Thromboembolism in Cancer Patients

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Apixaban

First Posted Date: 2022-07-18

Last Posted Date: 2022-10-26

Lead Sponsor: Bayer

Target Recruit Count: 2437

Registration Number: NCT05461807

Locations: 🇩🇪
Bayer, Wuppertal, Germany

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Phase 3

Recruiting

Conditions: Proteinuria
Chronic Kidney Disease
Children

Interventions: Drug: Finerenone (Kerendia, BAY94-8862)

First Posted Date: 2022-07-13

Last Posted Date: 2025-05-20

Lead Sponsor: Bayer

Target Recruit Count: 100

Registration Number: NCT05457283

Locations: 🇺🇸
Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, California, United States
🇺🇸
OHSU Doernbecher Children's Hospital - Neurology, Portland, Oregon, United States
🇲🇽
Sitio Alfredo Chew Wong | Aguascalientes, Mexico, Aguascalientes, Agguascalientes, Mexico

and more 137 locations

A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions

Completed

Conditions: Contrast Enhanced X-ray Based Examination

Interventions: Diagnostic Test: Iopromide (Ultravist, BAY86-4877)

First Posted Date: 2022-06-23

Last Posted Date: 2023-10-10

Lead Sponsor: Bayer

Target Recruit Count: 152233

Registration Number: NCT05428397

Locations: 🇩🇪
Bayer, Wuppertal, Germany

A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function

Phase 1

Completed

Conditions: Hepatic Impairment
Prevention of Thromboembolic Events
Acute Myocardial Infarction
Non-cardioembolic Ischemic Stroke
Atrial Fibrillation

Interventions: Drug: Asundexian (BAY2433334)

First Posted Date: 2022-06-15

Last Posted Date: 2023-08-29

Lead Sponsor: Bayer

Target Recruit Count: 27

Registration Number: NCT05419635

Locations: 🇩🇪
CRS-Kiel, Kiel, Schleswig-Holstein, Germany

A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the US

Completed

Conditions: Chronic Kidney Disease
Type 2 Diabetes Mellitus
Heart Failure

Interventions: Other: sMRA therapies

First Posted Date: 2022-06-07

Last Posted Date: 2023-09-21

Lead Sponsor: Bayer

Target Recruit Count: 600

Registration Number: NCT05407662

Locations: 🇺🇸
Many Locations, Whippany, New Jersey, United States

A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function

Phase 1

Withdrawn

Conditions: Diabetic Neuropathic Pain
Renal Impairment
Healthy Volunteers

Interventions: Drug: BAY2395840

First Posted Date: 2022-06-06

Last Posted Date: 2023-04-19

Lead Sponsor: Bayer

Registration Number: NCT05406219

A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers

Terminated

Conditions: Hemophilia A

Interventions: Other: No intervention

First Posted Date: 2022-05-27

Last Posted Date: 2023-11-28

Lead Sponsor: Bayer

Target Recruit Count: 14

Registration Number: NCT05395858

Locations: 🇺🇸
University of California, Davis, Sacramento, California, United States
🇺🇸
Tulane University, New Orleans, Louisiana, United States
🇺🇸
Regents of the University of Minnesota, Minneapolis, Minnesota, United States

A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting

Completed

Conditions: Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia
Irritable Bowel Syndrome
Functional Dyspepsia

Interventions: Drug: Iberogast (STW5-II, BAY98-7410)

First Posted Date: 2022-05-25

Last Posted Date: 2023-12-26

Lead Sponsor: Bayer

Target Recruit Count: 184

Registration Number: NCT05389709

Locations: 🇩🇪
Many Locations, Multiple Locations, Many Locations, Germany

A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years

Phase 1

Completed

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Hot Flashes
Healthy Volunteers

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Placebo

First Posted Date: 2022-05-19

Last Posted Date: 2022-07-27

Lead Sponsor: Bayer

Target Recruit Count: 16

Registration Number: NCT05381142

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy